Clinical activity of abiraterone plus prednisone in docetaxel-na(i)ve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2019,（2）
• 页码范围: 131-136
• 页数: 6页
• 语种: 英文

摘要

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-na(i)ve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC).A total of 146 patients with docetaxel-na(i)ve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai,China) in this retrospective cohort study.The efficacy endpoints were prostate-specific antigen response rate,prostate-specific antigen progression-free survival,clinical/radiographic progression-free survival,and overall survival in response to abiraterone plus prednisone.Significantly higher prostate-specific antigen response rate was found in docetaxel-na(i)ve group (54.4％,56/103) compared to docetaxel-resistant group (34.9％,15/43) (P =0.047).In addition,significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months,P =0.005),clinical or radiographic progression-free survival (17.0 vs 12.5 months,P =0.003),and overall survival (27.0 vs 18.0 months,P =0.016) were found in docetaxel-na(i)ve group compared to docetaxel-resistant group,respectively.The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival.To sum up,our data suggested that abiraterone plus prednisone was efficient in both docetaxel-na(i)ve and docetaxel-resistant Chinese patients.Moreover,higher PSA response rate and longer overall survival were observed in the docetaxel-nafve group,which suggested that abiraterone was more effective for docetaxel-na(i)ve patients than for docetaxel failures.